Trials / Completed
CompletedNCT05260684
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 716 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy. The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Encorafenib | 450 mg QD |
| DRUG | Binimetinib | 45 mg BID |
| DRUG | Vemurafenib | 960 mg BID for 28 days/cycle |
| DRUG | Cobimetinib | 60 mg QD for 21 days/cycle |
| DRUG | Dabrafenib | 150 mg BID |
| DRUG | Trametinib | 2 mg QD |
Timeline
- Start date
- 2022-01-17
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2022-03-02
- Last updated
- 2025-03-06
- Results posted
- 2025-03-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05260684. Inclusion in this directory is not an endorsement.